English

Navamedic enters into Nordic distribution agreement with Biotic Pharmacon

Report this content
Navamedic has entered into a distribution agreement for Woulgan® with Biotic Pharmacon.

- Woulgan® will be an important and prioritised product for Navamedic, significantly strengthening our position in the advanced wound care market. We are looking forward to our partnership with Biotec and to jointly secure a solid position in this high value market, says Tom Rönnlund, CEO of Navamedic.

Woulgan® is a premium priced product targeting hard to heal wounds in the professional wound care market. Clinical experience with Woulgan® demonstrate significantly improved healing, less pain and improved comfort during the treatment period compared to other therapies.

- Biotec is pleased to announce Navamedic as our Nordic partner for the distribution of Woulgan®. The agreement is in line with our strategy of signing up strong regional business partners for the distribution of Woulgan®. Navamedic has a solid position in the Nordic market and the ability to give Woulgan® the focus needed to make it a success. We are looking forward to work with the Navamedic team to position and secure the full commercial potential of Woulgan®, says Svein Lien, CEO of Biotec Pharmacon.

For additional information:                            

Svein Lien, CEO Biotec Pharmacon
+47 922 89 323
svein.lien@biotec.no                                              


Tom Rönnlund   CEO Navamedic
+46 727 320 321
tom.ronnlund@navamedic.com                      

 

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics.

Biotec Pharmacon is listed on the Oslo Stock Exchange (ticker: BIOTEC).

About Navamedic ASA

Navamedic ASA, a Norwegian medtech and pharmaceutical products company, is committed to serve patients, hospitals and pharmacies with excellent products across the Nordic region. Local presence, therapeutic expertise and access to healthcare specialists and hospitals in all Nordic markets have made Navamedic a preferred distribution partner for approximately 20 manufacturers of pharmaceuticals, medical devices and medical nutrition products. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

 

Subscribe